GlobeNewswire
-
Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock
13/11/2026 -
GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
13/11/2026 -
GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
13/11/2026 -
Milestone Scientific Reports Financial Results for Third Quarter 2026
13/11/2026 -
Milestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data
13/11/2026 -
Joint replacement in Charleston: a credentials checklist for choosing an orthopedic surgeon
13/11/2026 -
Contract Terms Shape How Quickly Outsourced Customer Support Can Scale Down After a Seasonal Spike
13/11/2026 -
BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
13/11/2026 -
Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update
13/11/2026 -
Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
13/11/2026 -
From the Fire Service to Counselling; Guelph Clinic Brings Community Experience into Psychotherapy
13/11/2026 -
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for systemic lupus erythematosus (SLE)
13/11/2026 -
Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
13/11/2026 -
Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
13/11/2026 -
Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
13/11/2026 -
ANGEL Brings Professional Coffee Water Solutions to the 2026 San Francisco Coffee Festival
13/11/2026 -
Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference
13/11/2026 -
Bavarian Nordic Launches Next Tranche of DKK 750 Million Share Buy-Back Program
13/11/2026 -
Bavarian Nordic Reports Strong Travel Health Growth in the Third Quarter and Confirms Solid Momentum for the Rest of the Year
13/11/2026
Pages